Program
Pemetrexed
Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.
Drug pagePemetrexed: every studyMany companies study it; this page follows only the 108 they lead. All 434 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 940 open or running | phase 4since Sep 22, 2006 | Apr 29, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 72 open or running | phase 3since Aug 18, 2009 | Aug 18, 2009 | Jun 30, 2027phase 3 · NCT05112965 |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Mar 31, 2014 | Mar 31, 2014 | none ahead |
| Hikma Pharmaceuticals | 10 open or running | phase 4since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Johnson & Johnsonits history only | 11 open or running | phase 3since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| NovoCureits history only | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| Polaris Groupits history only | 10 open or running | phase 3since Mar 5, 2016 | Mar 5, 2016 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Jun 22, 2006 | Jun 22, 2006 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hikma Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 26, 2018First study: phase 4 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03460678 · 9 enrolled · Jordan, Lebanon
TargetBeta
“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
The one study Hikma Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03460678Carcinoma, Non-Small-Cell Lung · Jordan, Lebanon | 4 | Terminated | Nov 14, 2018 | 9 |
How it is read
Names in the registry
- “Pemetrexed”, 74 entries
- “pemetrexed”, 51 entries
- “ALIMTA”, 7 entries
- “Pemetrexed/Cisplatin”, 2 entries
- “Pemetrexed/Carboplatin”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 73 studies
- Breast Neoplasms, 9 studies
- Neoplasms, 5 studies
- Ovarian Neoplasms, 4 studies
- Colorectal Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.